During the past decade, Mammazentrum HH am Krankenhaus Jerusalem conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 1 clinical trials were completed, i.e. on average, 16.7% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 1 clinical trials were completed. i.e. 25% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Mammazentrum HH am Krankenhaus Jerusalem" #1 sponsor was "West German Study Group" with 2 trials, followed by "AGO Study Group" with 1 trials sponsored, "Daiichi Sankyo, Inc." with 1 trials sponsored, "Odonate Therapeutics, Inc." with 1 trials sponsored and "Puma Biotechnology, Inc." with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Mammazentrum HH am Krankenhaus Jerusalem" #1 collaborator was "AstraZeneca" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 1 trials as a collaborator, "Genomic Health®, Inc." with 1 trials as a collaborator and "German Breast Group" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Mammazentrum HH am Krankenhaus Jerusalem" are "Breast Cancer" (2 trials), "Breast Cancer Female" (1 trials), "Early Stage HER2+ Breast Cancer" (1 trials), "Fallopian Tube Cancer" (1 trials) and "HER2-Positive Primary Breast Cancer" (1 trials). Many other conditions were trialed in "Mammazentrum HH am Krankenhaus Jerusalem" in a lesser frequency.

Most popular intervention types in "Mammazentrum HH am Krankenhaus Jerusalem" are "Drug" (6 trials). Other intervention types were less common.

The name of intervention was led by "Abemaciclib 50 MG; 150mg 1-0-1 per os" (1 trials), "Bevacizumab" (1 trials), "Budesonide" (1 trials), "Capecitabine" (1 trials) and "Carboplatin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Mammazentrum HH am Krankenhaus Jerusalem" are 3 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Mammazentrum HH am Krankenhaus Jerusalem". undefined are not yet recruiting, 3 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Mammazentrum HH am Krankenhaus Jerusalem, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Mammazentrum HH am Krankenhaus Jerusalem, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".